Clinical Trial Update: Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

Open-label Phase 2 trial evaluating OKN-007 in combination with temozolomide for recurrent glioblastoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Malignant Glioma

Drugs mentioned

• OKN-007
• Temozolomide (Temozolomide)

Snippet

Sponsor: Oblato, Inc. | Conditions: Recurrent Malignant Glioma, Brain Glioblastoma | Phase 2 | Status: COMPLETED